Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 3.639
Filtrar
1.
BMJ Glob Health ; 5(7)2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-32675068

RESUMEN

Are the steps that have been taken to arrest the spread of COVID-19 justifiable? Specifically, are they likely to have improved public health understood according to widely used aggregate population health measures, such as Quality Adjusted Life Years (QALYs) and Disability Adjusted Life Years (DALYs) as much or more than alternatives? This is a reasonable question, since such measures have been promoted extensively in global and national health policy by influential actors, and they have become almost synonymous with quantification of public health. If the steps taken against COVID-19 did not meet this test, then either the measures or the policies must be re-evaluated. There are indications that policies against COVID-19 may have been unbalanced and therefore not optimal. A balanced approach to protecting population health should be proportionate in its effects across distinct health concerns at a moment, across populations over time and across populations over space. These criteria provide a guide to designing and implementing policies that diminish harm from COVID-19 while also providing due attention to other threats to aggregate population health. They should shape future policies in response to this pandemic and others.


Asunto(s)
Infecciones por Coronavirus/economía , Salud Global , Pandemias/economía , Pandemias/ética , Neumonía Viral/economía , Salud Poblacional , Salud Pública/economía , Salud Pública/ética , Betacoronavirus , Infecciones por Coronavirus/epidemiología , Política de Salud , Humanos , Neumonía Viral/epidemiología , Años de Vida Ajustados por Calidad de Vida
8.
Am J Trop Med Hyg ; 102(6): 1172-1174, 2020 06.
Artículo en Inglés | MEDLINE | ID: mdl-32358952

RESUMEN

The first case of novel coronavirus disease (COVID-19) in the Dominican Republic coincided with a period of political crisis. Distrust in governmental institutions shaped the critical phase of early response. Having a weak public health infrastructure and a lack of public trust, the Ministry of Health (MoH) began the fight against COVID-19 with a losing streak. Within 45 days of the first reported case, the political crisis and turmoil caused by "fake news" are limiting the capacity and success of the MoH response to the pandemic.


Asunto(s)
Antivirales/uso terapéutico , Betacoronavirus/patogenicidad , Infecciones por Coronavirus/epidemiología , Pandemias , Neumonía Viral/epidemiología , Medios de Comunicación Sociales/ética , Anticuerpos Monoclonales Humanizados/uso terapéutico , Antivirales/provisión & distribución , Azitromicina/provisión & distribución , Azitromicina/uso terapéutico , Betacoronavirus/efectos de los fármacos , Desórdenes Civiles , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/economía , Disentimientos y Disputas , República Dominicana/epidemiología , Reposicionamiento de Medicamentos , Humanos , Hidroxicloroquina/provisión & distribución , Hidroxicloroquina/uso terapéutico , Ivermectina/provisión & distribución , Ivermectina/uso terapéutico , Pandemias/economía , Neumonía Viral/tratamiento farmacológico , Neumonía Viral/economía , Política , Salud Pública/economía , Salud Pública/tendencias , Confianza/psicología
14.
Eur J Hum Genet ; 28(6): 719-723, 2020 06.
Artículo en Inglés | MEDLINE | ID: mdl-32415272

RESUMEN

ELIXIR, the European research infrastructure for life science data, provides open access to data, tools and workflows in the response to the COVID-19 pandemic. ELIXIR's 23 nodes have reacted swiftly to support researchers in their combined efforts against the pandemic setting out three joint priorities: 1. Connecting national COVID-19 data platforms to create federated European COVID-19 Data Spaces; 2. Fostering good data management to make COVID-19 data open, FAIR and reusable over the long term; 3. Providing open tools, workflows and computational resources to drive reproducible and collaborative science. ELIXIR's strategy is based on the support given by our national nodes - collectively spanning over 200 institutes - to research projects and on partnering with community initiatives to drive development and adoption of good data practice and community driven standards. ELIXIR Nodes provide support activities locally and internationally, from provisioning compute capabilities to helping collect viral sequence data from hospitals. Some Nodes have prioritised access to their national cloud and compute facilities for all COVID-19 research projects, while others have developed tools to search, access and share all data related to the pandemic in a national healthcare setting.


Asunto(s)
Betacoronavirus/patogenicidad , Investigación Biomédica/organización & administración , Infecciones por Coronavirus/epidemiología , Difusión de la Información/métodos , Cooperación Internacional/legislación & jurisprudencia , Pandemias , Neumonía Viral/epidemiología , Betacoronavirus/genética , Infecciones por Coronavirus/genética , Infecciones por Coronavirus/patología , Infecciones por Coronavirus/virología , Conjuntos de Datos como Asunto , Europa (Continente)/epidemiología , Humanos , Difusión de la Información/ética , Neumonía Viral/genética , Neumonía Viral/patología , Neumonía Viral/virología , Salud Pública/economía , Flujo de Trabajo
15.
Eur J Hum Genet ; 28(6): 728-731, 2020 06.
Artículo en Inglés | MEDLINE | ID: mdl-32444797

RESUMEN

During the COVID-19 pandemic, the European biobanking infrastructure is in a unique position to preserve valuable biological material complemented with detailed data for future research purposes. Biobanks can be either integrated into healthcare, where preservation of the biological material is a fork in clinical routine diagnostics and medical treatment processes or they can also host prospective cohorts or material related to clinical trials. The paper discussed objectives of BBMRI-ERIC, the European research infrastructure established to facilitate access to quality-defined biological materials and data for research purposes, with respect to the COVID-19 crisis: (a) to collect information on available European as well as non-European COVID-19-relevant biobanking resources in BBMRI-ERIC Directory and to facilitate access to these via BBMRI-ERIC Negotiator platform; (b) to help harmonizing guidelines on how data and biological material is to be collected to maximize utility for future research, including large-scale data processing in artificial intelligence, by participating in activities such as COVID-19 Host Genetics Initiative; (c) to minimize risks for all involved parties dealing with (potentially) infectious material by developing recommendations and guidelines; (d) to provide a European-wide platform of exchange in relation to ethical, legal, and societal issues (ELSI) specific to the collection of biological material and data during the COVID-19 pandemic.


Asunto(s)
Betacoronavirus/patogenicidad , Investigación Biomédica/organización & administración , Infecciones por Coronavirus/epidemiología , Difusión de la Información/métodos , Cooperación Internacional/legislación & jurisprudencia , Pandemias , Neumonía Viral/epidemiología , Antivirales/uso terapéutico , Inteligencia Artificial , Betacoronavirus/efectos de los fármacos , Betacoronavirus/genética , Bancos de Muestras Biológicas/provisión & distribución , Ensayos Clínicos como Asunto , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/genética , Conjuntos de Datos como Asunto , Europa (Continente)/epidemiología , Humanos , Difusión de la Información/ética , Neumonía Viral/diagnóstico , Neumonía Viral/tratamiento farmacológico , Neumonía Viral/genética , Guías de Práctica Clínica como Asunto , Salud Pública/economía
16.
Am J Trop Med Hyg ; 102(6): 1178-1180, 2020 06.
Artículo en Inglés | MEDLINE | ID: mdl-32314700

RESUMEN

The 2019 novel coronavirus disease (COVID-19) pandemic highlights the experience of communities in the global South that have grappled with vulnerability and scarcity for decades. In the global North, many frontline workers are now being similarly forced to provide and ration care in unprecedented ways, with minimal guidance. We outline six reflections gained as Western practitioners working in resource-denied settings which inform our current experience with COVID-19. The reflections include the following: managing trauma, remaining flexible in dynamic situations, and embracing discomfort to think bigger about context-specific solutions to collectively build back our systems. Through this contextualized reflection on resilience, we hope to motivate strength and solidarity for providers, patients, and health systems, while proposing critical questions for our response moving forward.


Asunto(s)
Betacoronavirus/patogenicidad , Infecciones por Coronavirus/epidemiología , Asignación de Recursos para la Atención de Salud/ética , Accesibilidad a los Servicios de Salud/economía , Pandemias , Neumonía Viral/epidemiología , Salud Pública/economía , Toma de Decisiones Clínicas/ética , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/economía , Infecciones por Coronavirus/terapia , Asignación de Recursos para la Atención de Salud/economía , Disparidades en Atención de Salud/ética , Humanos , Relaciones Interpersonales , América del Norte/epidemiología , Pandemias/economía , Neumonía Viral/diagnóstico , Neumonía Viral/economía , Neumonía Viral/terapia , Guías de Práctica Clínica como Asunto , Salud Pública/ética , Incertidumbre
19.
Nat Commun ; 11(1): 1745, 2020 04 21.
Artículo en Inglés | MEDLINE | ID: mdl-32317698

RESUMEN

Invasive alien species (IAS) can substantially affect ecosystem services and human well-being. However, quantitative assessments of their impact on human health are rare and the benefits of implementing IAS management likely to be underestimated. Here we report the effects of the allergenic plant Ambrosia artemisiifolia on public health in Europe and the potential impact of the accidentally introduced leaf beetle Ophraella communa on the number of patients and healthcare costs. We find that, prior to the establishment of O. communa, some 13.5 million persons suffered from Ambrosia-induced allergies in Europe, causing costs of Euro 7.4 billion annually. Our projections reveal that biological control of A. artemisiifolia will reduce the number of patients by approximately 2.3 million and the health costs by Euro 1.1 billion per year. Our conservative calculations indicate that the currently discussed economic costs of IAS underestimate the real costs and thus also the benefits from biological control.


Asunto(s)
Agentes de Control Biológico , Malezas/crecimiento & desarrollo , Rinitis Alérgica Estacional , Control de Malezas/métodos , Ambrosia , Animales , Escarabajos , Europa (Continente) , Humanos , Salud Pública/economía , Salud Pública/estadística & datos numéricos , Rinitis Alérgica Estacional/epidemiología , Rinitis Alérgica Estacional/prevención & control
20.
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA